GCGiovanni Cenderello

Giovanni Cenderello

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Giovanni Cenderello has a total of 214 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Weight, blood glucose and lipid changes in the course of long‐acting cabotegravir + rilpivirine: A prospective two‐year evaluation

    by Lucia Taramasso, Gaia Cologgi, Elena Ricci, Sergio Ferrara, Giancarlo Orofino, Nicola Squillace, Emanuele Pontali, Barbara Menzaghi, Eleonora Sarchi, Giovanni Cenderello, et al.

    Introduction: There are little real‐world data from observational cohorts regarding the impact of long‐acting (LA) cabotegravir (CAB) and rilpivirine (RPV) treatment on weight and blood lipids. Methods: This multicentre, prospective, observational study included people with human immunodeficiency virus initiating LA CAB+RPV within the Surveillance Cohort Long‐Term Toxicity Antiretrovirals (SCOLTA) cohort. Weight and cholesterol levels (total, high‐density lipoprotein cholesterol (HDL) and low‐density lipoprotein cholesterol (LDL)) were collected at six‐month intervals within two‐year follow‐ups. A multivariate mixed linear model was run to determine the association between change from baseline and participants' characteristics. Results: A total of 671 participants were enrolled, with a median follow‐up of 22 (interquartile range [IQR]: 13–29) months. The median age was 49 years (IQR 40–58) and median duration of antiretroviral therapy (ART) was 10.3 years (IQR 6.4–16.7). There was no significant change in mean weight after 1 year and 2 years, with differences of −0.25 kg (95% CI: −0.59 to +0.08, p = 0.14) and −0.18 kg (95% CI: −0.70 to +0.33, p = 0.48), respectively. The multivariable analysis revealed that weight change was significantly associated with baseline body mass index (BMI). People with obesity and overweight experienced a significantly greater reduction in weight, compared to those of normal weight (mean estimate −1.66 kg, 95% CI −2.69 to −0.64, and −0.72 kg, 95% CI: −1.24 to −0.19, respectively). Total cholesterol (+6 mg/dL, 95% CI: +1.4 to +10.7), HDL cholesterol (+2.9 mg/dL, 95% CI: +1.2 to +4.7) and LDL cholesterol (+2.4 mg/dL, 95% CI: −1.8 to +6.6) increased at 2 years, with no change in the total/HDL ratio. Conclusions: Body weight remained stable in the SCOLTA cohort after switching to LA CAB+RPV for 2 years. There was a modest but significant increase in cholesterol levels, though the ratio of total to HDL cholesterol remained stable.

  • Open Access

    Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors

    by Tommaso Clemente, Laura Galli, Riccardo Lolatto, Roberta Gagliardini, Filippo Lagi, Micol Ferrara, Anna Maria Cattelan, Emanuele Focà, Antonio Di Biagio, Adriana Cervo, et al.

    Purpose: The PRESTIGIO Registry was established in 2017 to collect clinical, virological and immunological monitoring data from people living with HIV (PLWH) with documented four-class drug resistance (4DR). Key research purposes include the evaluation of residual susceptibility to specific antiretrovirals and the validation of treatment and monitoring strategies in this population. Participants: The PRESTIGIO Registry collects annual plasma and peripheral blood mononuclear cell samples and demographic, clinical, virological, treatment and laboratory data from PLWH followed at 39 Italian clinical centres and characterised by intermediate-to-high genotypic resistance to ≥1 nucleoside reverse transcriptase inhibitors, ≥1 non-nucleoside reverse transcriptase inhibitors, ≥1 protease inhibitors, plus either intermediate-to-high genotypic resistance to ≥1 integrase strand transfer inhibitors (INSTIs) or history of virological failure to an INSTI-containing regimen. To date, 229 people have been recorded in the cohort. Most of the data are collected from the date of the first evidence of 4DR (baseline), with some prebaseline information obtained retrospectively. Samples are collected from the date of enrollment in the registry. Findings to date: The open-ended cohort has been used to assess (1) prognosis in terms of survival or development of AIDS-related or non-AIDS-related clinical events; (2) long-term efficacy and safety of different antiretroviral regimens and (3) virological and immunological factors predictive of clinical outcome and treatment efficacy, especially through analysis of plasma and cell samples. Future plans: The registry can provide new knowledge on how to implement an integrated approach to study PLWH with documented resistance to the four main antiretroviral classes, a population with a limited number of individuals characterised by a high degree of frailty and complexity in therapeutic management. Given the scheduled annual updates of PLWH data, the researchers who collaborate in the registry can send study proposals at any time to the steering committee of the registry, which evaluates every 3 months whether the research studies can be conducted on data and biosamples from the registry and whether they are aimed at a better understanding of a specific health condition, the emergence of comorbidities or the effect of potential treatments or experimental drugs that may have an impact on disease progression and quality of life. Finally, the research studies should aim to be inclusive, innovative and in touch with the communities and society as a whole. Trial registration number: NCT04098315 .


  • Open Access

    SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study

    by Alessandra Mangia, Giovanni Cenderello, Massimiliano Copetti, Gabriella Verucchi, Valeria Piazzolla, Celeste Lorusso, Rosanna Santoro, Maria Maddalena Squillante, Alessandra Orlandini, Rosalba Minisini, et al.

    In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. No real-life data on genotype 3 (GT3) cirrhotic patients with portal hypertension are available. The aim of this study was to assess the effectiveness of SOF/VEL in GT3 cirrhotics with portal hypertension. Patients with GT3 and advanced cirrhosis were treated for 12 weeks with SOF/VEL without ribavirin at five different centers in Italy from June 2017 to August 2018 and their SVR12 was assessed. Of the 227 GT3 cirrhotics evaluated, 205 met the inclusion criteria and 111 had transient elastography results ≥20 KPa. SVR12 was 97.6% (95% CI 94.4–98.9), rates were 99.1% (95% CI 95.7–99.8) in patients with ≥20 KPa and 95.8% (95% CI 89.5–98.3) in those with p = 0.18). Analyzed by presence of esophageal varices, the SVR12 rates were 98.4% (95% CI 91.4–99.7) and 97.1% (95% CI 92.9–98.9) in patients without and with varices, respectively (p = 1.0). In real life, SOF/VEL GT3 cirrhotic patients with evidence of portal hypertension can achieve SVR12 levels comparable to those of patients without portal hypertension. These SVR12 rates are similar to what is reported in compensated cirrhosis treated within clinical trials.


  • HCV elimination plan leads to significant benefits in managing liver-related diseases and hospital interventions: a regional simulation

    by Giovanni Cenderello, Lucia Taramasso, Domenico Marra, Patrizia Orcamo, Ambra Pasa, Antonio Di Biagio

    Objectives: This article presents a 3-year budget impact simulation on the effects of a chronic Hepatitis C (HCV) eradication plan in real-life costs incurred by the Regional Health Service. Methods: The Liguria Region network performed a prospective 3-year (2017–2019) timeframe horizon trends simulation analysis focusing on management interventions and costs. It involved all the eight prescribing centers in the region, starting from retrospective historical performance data and assuming the impact of sustained viral response rates for patients treated for HCV. Data on hospital admissions, medical visits, number of patients, and deaths were collected through the healthcare database. Results: At the beginning of 2017, 2,940 patients were eligible for HCV treatment with direct-acting antivirals. Assuming to treat this entire population with a success rate of 90%, the events related to liver complications in the horizon would decrease to 5,538 cumulatively (−35%), with a 27% reduction of direct costs, showing a global savings of 24,779.024 Euros. Conclusion: Treating the entire eligible HCV population would lead to significant benefits and savings in managing liver-related diseases and their direct costs, opening opportunities to re-think new settings for the future organization of liver disease management in the regional health system.


  • Open Access

    A case report of mucocutaneous tuberculosis after orthotopic liver transplantation: a challenging diagnosis

    by Niccolò Riccardi, Giovanni Cenderello, Emanuele Borroni, Mariangela Rutigliani, Daniela Maria Cirillo

    Mycobacterium tuberculosis is responsible for high morbidity and mortality in immune-compromised hosts. We present a rare case of cutaneous tuberculosis after orthotopic liver transplantation without involvement of any other organs. TB risk-factors assessment, careful LTBI screening and treatment according to national guidelines, as well as a reduction in missed opportunity for prevention are necessary to avoid MTB related disease in fragile patients.


    • 10 October 2017
      • Vol. 40  (4) , 227-233

    Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents.

    by Lucia Taramasso, Giovanni Cenderello, Niccolò Riccardi, Simone Tunesi, Antonio Di Biagio

    Integrase strand transfer inhibitors (INSTIs) are the preferred third agent in first-line antiretroviral therapies. Raltegravir (RAL) was the first INSTI to be approved and used in naïve and experienced patients. Due to its good tolerability and low side effects, RAL has been largely used also in hepatitis coinfected patients. Many years of experience in RAL use now allow literature evidence to be gathered on its safety in HIV/HCV-co-infected patients pre, during and post direct acting agents (DAA) treatment, at all possible stages. In both clinical trials and published case series, RAL has been well tolerated in patients harboring HCV co-infection and also in cirrhotic patients with mild hepatic impairment. Literature data show no major interactions or the need for dose adjustments with any of the DAA currently in use for HCV treatment, or with ribavirine. Hence, RAL can be safely administered during HCV treatment with DAA and may be used as a "temporary" regimen in patients who do not present major integrase-inhibitor mutations. Moreover, its characteristics are also favorable in case of orthotropic liver transplantation, both for the evidence of hepatic safety and for possible co-administration with immunosuppressant agents.


  • Open Access

    A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data

    by Amedeo F. Capetti, Maria Vittoria Cossu, Giancarlo Orofino, Gaetana Sterrantino, Giovanni Cenderello, Giuseppe V. De Socio, Anna Maria Cattelan, Alessandro Soria, Stefano Rusconi, Niccolò Riccardi, et al.

    Dolutegravir (DTG) plus darunavir/ritonavir (DRV/r) is a simple combination of drugs that has the best genetic barrier to HIV-1 resistance and may be fit for salvage therapy. All HIV-1-infected subjects treated with DTG plus DRV/r between March 2014 and September 2015 in eight Italian centres were included in the analysis. The main metabolic data, efficacy parameters and safety data routinely collected were provided. This observational study is aimed to assess the efficacy of such approach. The primary end-point was the proportion of subjects achieving or maintaining virologic suppression <50 copies/mL at week 24. Secondary end points were maintaining virologic suppression in the follow-up (weeks 48 and 96) and safety. One hundred and thirty subjects were followed for a median of 56 months. Reasons for switching were simplification (44.6%), viral failure (30%), toxicity (16.9%), non-adherence (4.6%), persistent low-level viremia (3.1%), and drug-drug interaction (0.8%). At baseline, 118 subjects had documented resistance to 1 to 5 antiretroviral classes while 12 had viral rebound at a time when genotypic tests were not yet available. Seventeen and 14 subjects took DRV/r and DTG twice daily, respectively. One subject was lost to follow-up, one discontinued for liver enzymes’ elevation, one died of illicit drug abuse and one of cancer-related complications. The proportion of subjects with ongoing HIV replication dropped from 40% to 6.1%. Those with undetectable viral load increased from 38.5% to 76.2%. At week 48, 17.7% had HIV RNA between 1 and 49 copies/mL. The number of subjects with altered serum glucose, creatinine, ALT, AST, total-, HDL- and LDL-cholesterol, triglycerides and MDRD <90 mL/min decreased by week 48, while those having MDRD <60 mL/min remained 4.6%. Overall 90/283 baseline laboratory alterations returned to normality. Switching to DTG plus DRV/r proved to be safe, suppressing viral replication without metabolic impact.


  • Open Access

    Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis

    by Giovanni Cenderello, Caterina Fanizza, Simona Marenco, Laura Ambra Nicolini, Stefania Artioli, Isabella Baldissarro, Chiara Dentone, Pasqualina De Leo, Antonio Di Biagio

    Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis Giovanni Cenderello,1 Caterina Fanizza,2 Simona Marenco,3 Laura Ambra Nicolini,4 Stefania Artioli,5 Isabella Baldissarro,3 Chiara Dentone,6 Pasqualina De Leo,7 Antonio Di Biagio4 1SC Malattie Infettive, EO Ospedali Galliera, 2Rete ligure HIV, 3SSD Epatologia, AOU S. Martino, 4Clinica Malattie Infettive, AOU S. Martino, Genoa, 5SC Malattie Infettive ASL5 La Spezia, 6SC Malattie Infettive, ASLâ


  • Open Access

    Is it still worthwhile to perform quarterly cd4+ t lymphocyte cell counts on hiv-1 infected stable patients?

    by Antonio Di Biagio, Marta Ameri, Davide Sirello, Giovanni Cenderello, Enrico Di Bella, Lucia Taramasso, Barbara Giannini, Mauro Giacomini, Claudio Viscoli, Giovanni Cassola, et al.

    In the last 20 years routine T CD4+ lymphocyte (CD4+) cell count has proved to be a key factor to determine the stage of HIV infection and start or discontinue of prophylaxis for opportunistic infections. However, several studies recently showed that in stable patients on cART a quarterly CD4+ cell count monitoring results in limited (or null) clinical relevance. The research is intended to investigate whether performing quarterly CD4+ cell counts in stable HIV-1 patients is still recommendable and to provide a forecast of the cost saving that could be achieved by reducing CD4+ monitoring in such a category of patients. The study is based on data referring to all HIV-infected patients > 18 years of age being treated at two large infectious diseases units located in the metropolitan area of Genoa, Italy. The probability of CD4+ cell counts dropping below a threshold value set at 350 cells/mm3 is assessed using confidence intervals and Kaplan-Meier survival estimates, whereas multivariate Cox analysis and logistic regression are implemented in order to identify factors associated with CD4+ cell count falls below 350 cells/mm3. Statistical analysis reveals that among stable patients the probability of maintaining CD4+ >350 cell/mm3 is more than 98%. Econometric models indicate that HCV co-infection and HIV-RNA values >50 copies/mL in previous examinations are associated with CD4+ falls below 350 cells/mm3. Moreover, results suggest that the cost saving that could be obtained by reducing CD4+ examinations ranges from 33 to 67%. Empirical findings shows that patients defined as stable at enrollment are highly unlikely to experience a CD4+ value <350 cell/mm3 in the space/arc of a year. The research supports a recommendation for annual CD4+ monitoring in stable HIV-1 patients.


  • An unexpected waterborne traveller

    by N. Riccardi, G. Cenderello, M. Costa, G. Cassola